Research facilities seeking high-purity CJC No DAC and Ipamorelin co-formulations require rigorous analytical validation and lot-specific verification. PX1 Research supplies USA-manufactured CJC-1295 No DAC (Mod GRF 1-29) combined with Ipamorelin for in vitro and preclinical research applications. Every lot is independently verified via RP-HPLC and ESI-MS to ensure strict chemical purity and identity.
Research facilities seeking high-purity CJC No DAC and Ipamorelin co-formulations require rigorous analytical validation and lot-specific verification. PX1 Research supplies USA-manufactured CJC-1295 No DAC (Mod GRF 1-29) combined with Ipamorelin for in vitro and preclinical research applications. Every lot is independently verified via RP-HPLC and ESI-MS to ensure strict chemical purity and identity.
The CJC No DAC / Ipamorelin research compound blend combines two synthetic secretagogues—Mod GRF 1-29 (CJC-1295 without Drug Affinity Complex) and Ipamorelin—formulated specifically for laboratory evaluation of dual-receptor growth factor signaling. Sourcing this compound requires stringent vendor verification to guarantee high analytical purity, low endotoxin levels, and consistent batch stoichiometry for reproducible in vitro and animal studies.
When acquiring a CJC-1295 No DAC / Ipamorelin blend for institutional research, principal investigators must ensure the material is accompanied by lot-specific documentation. PX1 Research synthesizes all compounds in domestic, ISO 17025-compliant and GMP-aligned facilities, supplying full third-party analytical certification with every unit.
The primary objective of combining CJC-1295 No DAC with Ipamorelin in experimental protocols is to evaluate the synergistic activation of two distinct neuroendocrine pathways. Mod GRF 1-29 functions as a Growth Hormone Releasing Hormone (GHRH) receptor agonist, binding to GHRH receptors on pituitary somatotrophs to stimulate cyclic adenosine monophosphate (cAMP) accumulation and downstream signaling cascades.
Concurrently, Ipamorelin acts as a selective agonist at the Growth Hormone Secretagogue Receptor (GHS-R1a), mimicking the action of endogenous ghrelin. In vitro assays demonstrate that co-activating GHRH and GHS-R1a receptors produces a amplified release of growth hormone compared to activating either receptor in isolation. Preclinical models evaluating growth hormone secretagogues show that this dual-pathway stimulation mimics natural physiological pulsatility without causing receptor desensitization.
Understanding the molecular distinctions between CJC-1295 variants is critical for protocol design. CJC-1295 No DAC, chemically identified as Modified GRF 1-29, is a 29-amino acid peptide derived from the naturally occurring GHRH(1-29) sequence. Four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) are incorporated into its primary structure to enhance enzymatic resistance against dipeptidyl peptidase IV (DPP-IV) degradation while retaining a compact terminal half-life of approximately 30 minutes in plasma.
In contrast, CJC-1295 DAC features an added maleimidopropionyl lysine linker (Drug Affinity Complex) that covalently binds to circulating serum albumin. This modification extends the half-life to several days, leading to continuous, tonic receptor activation. For research applications designed to model natural, pulsatile signaling dynamics, CJC-1295 No DAC remains the preferred analogue.
Published preclinical literature highlights several key mechanisms observed during dual GHRH and GHS-R agonist administration. In vitro pituitary cell culture studies indicate that GHRH receptor signaling activates protein kinase A (PKA), whereas GHS-R1a activation by Ipamorelin mobilizes intracellular calcium via the phosphatidylinositol pathway (PKA/PKC dual-signaling system).
Data compiled within our research library hub document that when both signaling pathways are stimulated simultaneously, intracellular calcium influx and cAMP generation exhibit a non-additive, synergistic curve. Animal studies further demonstrate that this dual activation promotes transcription of insulin-like growth factor 1 (IGF-1) mRNA in hepatic tissue while maintaining normal baseline pituitary response curves.
Evaluating secretagogue dynamics requires comparing CJC-1295 No DAC and Ipamorelin against other established compounds in the same functional class. Traditional first-generation secretagogues often exhibit off-target receptor affinities that complicate analytical outcomes.
For example, while earlier peptides like Sermorelin share GHRH receptor affinity, Sermorelin lacks the four stabilizing amino acid substitutions present in Mod GRF 1-29, resulting in rapid enzymatic cleavage in physiological buffers. Similarly, older ghrelin mimetics such as GHRP-2 and GHRP-6 exhibit marked off-target activation, stimulating adrenocorticotropic hormone (ACTH), cortisol, and prolactin release in animal models. Ipamorelin is unique among GHS-R agonists for its extreme selectivity, showing zero significant affinity for ACTH or prolactin receptors in published assays.
Proper reconstitution procedures are essential to maintain peptide integrity and prevent aggregation prior to benchtop experimentation. Lyophilized CJC No DAC / Ipamorelin co-formulations should be brought to room temperature in a laminar flow hood before introducing solvent to minimize moisture condensation within the vial.
Reconstitution for in vitro assays is typically achieved using sterile bacteriostatic water (0.9% benzyl alcohol) or laboratory-grade sterile normal saline. Solvents should be allowed to run gently down the inner glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirl mixing is recommended; mechanical agitation or violent shaking must be avoided to prevent shear stress and peptide denaturation.
Lyophilized peptide vials should be stored in deep-freeze conditions (-20°C to -80°C) for long-term storage, where they remain chemically stable for up to 24 months. Vials must be protected from direct light exposure and stored in sealed containers with desiccant packs to prevent moisture absorption.
Once reconstituted into aqueous solution, the compound should be stored at 2°C to 8°C and evaluated within 30 days when using bacteriostatic solvents. Repeated freeze-thaw cycles must be strictly avoided, as thermal cycling causes physical degradation and cleavage of the peptide backbone. Small experimental aliquots should be prepared immediately following initial reconstitution.
The analytical validity of experimental data relies entirely on the purity of the research reagents used. Low-purity peptide samples containing unreacted amino acid sequences or trifluoroacetic acid (TFA) salts can yield false-positive or toxic cellular responses in tissue cultures.
PX1 Research enforces strict quality control standards for all USA-manufactured research peptides. Every production lot undergoes independent analytical validation: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) verifies chemical purity (>99%), Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular mass, and Limulus Amebocyte Lysate (LAL) assays certify that bacterial endotoxin levels remain below industry thresholds (<0.01 EU/mg).
PX1 Research supports university laboratories, contract research organizations (CROs), and private biotechnology enterprises requiring standardized reagent batches for longitudinal studies. Maintaining consistent peptide sequence fidelity and identical counter-ion profiles across multiple study phases is vital for data integrity.
Institutions can establish dedicated institutional purchasing pathways through our bulk lab account services. All orders ship directly from ISO-aligned manufacturing centers located in California and Arizona, providing rapid fulfillment, lot-tracked shipping documentation, and chain-of-custody verification.
What is the primary distinction between CJC-1295 No DAC and CJC-1295 With DAC?
CJC-1295 No DAC (Mod GRF 1-29) lacks the Drug Affinity Complex (maleimidopropionyl lysine linker), resulting in a short half-life (~30 minutes) that mimics pulsatile GHRH release. CJC-1295 With DAC binds to serum albumin, extending its half-life to several days and causing continuous stimulation.
Why are CJC-1295 No DAC and Ipamorelin combined in research studies?
Preclinical studies show that co-administering a GHRH agonist (Mod GRF 1-29) and a GHS-R1a agonist (Ipamorelin) produces a synergistic elevation of growth hormone release that exceeds the additive effects of either peptide evaluated individually.
How does PX1 Research verify the purity of CJC No DAC / Ipamorelin?
Every lot undergoes independent third-party analysis using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity (>99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) for structural mass confirmation. Full COAs are provided per lot.
What solvent is recommended for reconstituting this research compound?
For standard laboratory assays, sterile bacteriostatic water (0.9% benzyl alcohol) or sterile laboratory-grade saline is typically used under aseptic conditions within a laminar flow hood.
What are the endotoxin limits for PX1 Research compounds?
All research peptides supplied by PX1 Research are verified via Limulus Amebocyte Lysate (LAL) testing to contain endotoxin levels well below strictly defined laboratory limits (<0.01 EU/mg).
Does Ipamorelin cause off-target elevation of cortisol or prolactin in assays?
In vitro and animal model assays demonstrate that Ipamorelin is highly selective for the GHS-R1a receptor and does not induce significant off-target secretion of ACTH, cortisol, or prolactin, unlike older GHRP compounds.
How should reconstituted peptide solutions be stored in the lab?
Reconstituted liquid aliquots should be stored at 2°C to 8°C for short-term bench use (up to 30 days in bacteriostatic water). Repeated freeze-thaw cycles must be avoided to prevent sequence degradation.
Where are PX1 Research compounds synthesized and shipped from?
PX1 Research compounds are synthesized in domestic US facilities operating under ISO 17025 and GMP-aligned standards, shipping directly from distribution facilities in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.